Post
Nikhil Krishnan @nikillinit · Jan 17, 2022
  • From Twitter

this is a great read from @46brooklyndata on the failures of medicare part D's prescription drug benefit design using Tecifidera (an MS drug) as a case study for when generics enter the market and get prevented from being used some damning points:

Recommended by 1 person
1 mention
Share on Twitter Repost
Replies
Reply
No replies yet